

Záver

Rôzne bakteriálne druhy môžu prispievať k patogenéze aterosklerózy rôznymi mechanizmami, vrátane produkcie toxínov a metabolitov, stimulá-

ciou zápalových reakcií, či inváziou buniek hostiteľa. Cieľom budúceho pátrania je lepšie pochopiť mechanizmy, ktorými mikrobióm ovplyvňuje vývoj aterosklerózy, a identifikovať nové terapeutické ciele pre prevenciu a liečbu.

PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti: Publikace byla zpracována s využitím uvedené literatury a nebyla publikována ani zaslána k recenznímu řízení do jiného média. **Střet zájmů:** Žádný. **Financování:** Ne. **Poděkování:** Ne. **Registrace v databázích:** N/A. **Projednáni etickou komisí:** N/A.

LITERATURA

1. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2021;42(34):3227-3337.
2. Rinninella E, Raoul P, Cintoni M, et al. What Is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. *Microorganisms* 2019, 7, 14.
3. Sonnenburg JL, Bäckhed, F. Diet-microbiota interactions as moderators of human metabolism. *Nature*. 2016;535:56-64
4. Olvera-Rosales LB, Cruz-Guerrero AE, Ramírez-Moreno E, et al. Impact of the Gut Microbiota Balance on the Health-Disease Relationship: The Importance of Consuming Probiotics and Prebiotics. *Foods*. 2021;10(6):1261.
5. Bäckhed F, Fraser CM, Ringel Y, et al. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. *Cell Host Microbe*. 2012;12:611-22.
6. Jonsson A, Bäckhed F. Role of gut microbiota in atherosclerosis. *Nat Rev Cardiol*. 2017;14:79-87.
7. Liu Q, Li YC, Song X, et al. Both gut microbiota and cytokines act to atherosclerosis in ApoE^{-/-} mice. *Microb Pathog*. 2019;103827.
8. Zhu Q, Gao R, Zhang Y, et al. Dysbiosis signatures of gut microbiota in coronary artery disease. *Physiol Genomics*. 2018.
9. Yvan-Charvet L, Welch C, Pagler TA, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. *Circulation*. 2008;118(18):1837-1847.
10. Chacón MR, Lozano-Bartolomé J, Portero-Otín M, et al. The gut mycobiome composition is linked to carotid atherosclerosis. *Benef Microbes*. 2018;9:185-98.
11. Kozarov E. Bacterial invasion of vascular cell types: vascular infectology and atherogenesis. *Future Cardiol*. 2012;8(1):123-138.
12. Liu X, Xie Z, Sun M, Wang X, Li J, Cui J, et al. Plasma trimethylamine N-oxide is associated with vulnerable plaque characteristics in CAD patients as assessed by optical coherence tomography. *Int J Cardiol*. 2018;265:18-23.
13. Koren O, Spor A, Felin J, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. *Proc Natl Acad Sci U S A*. 2011;108 Suppl 1(Suppl 1):4592-4598.
14. Karlsson FH, Fålk F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. *Nat Commun*. 2012;3:1245.
15. Choroszy M, Litwinowicz K, Bednarz R, et al. Human Gut Microbiota in Coronary Artery Disease: A Systematic Review and Meta-Analysis. *Metabolites*. 2022;12(12):1165.
16. Kazemian N, Mahmoudi M, Halperin F, et al. Gut Microbiota and Cardiovascular Disease: Opportunities and Challenges. *Microbiome* 2020, 8, 36.
17. Kriaa A, Bourgin M, Potiron, A, et al. Microbial Impact on Cholesterol and Bile Acid Metabolism: Current Status and Future Prospects. *J Lipid Res*. 2019;60:323-332.
18. Wexler A.G, Goodman A.L. An Insider's Perspective: Bacteroides as a Window into the Microbiome. *Nat. Microbiol*. 2017;2:17026.
19. Yoshida N, Yamashita T, Kishino S, et al. A Possible Beneficial Effect of Bacteroides on Faecal Lipopolysaccharide Activity and Cardiovascular Diseases. *Sci. Rep*. 2020;10:13009.
20. Yoshida N, Emoto T, Yamashita T, et al. Bacteroides Vulgatus and Bacteroides Dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. *Circulation* 2018;138:2486-2498.
21. Sasaki N, Takeuchi H, Kitano S, et al. Dynamic analysis of Porphyromonas gingivalis invasion into blood capillaries during the infection process in host tissues using a vascularized three-dimensional human gingival model. *Biomater Sci*. 2021;9(19):6574-6583.
22. Grigorieva I. Atherosclerosis and trimethylamine-N-oxide — the gut microbiota potential. *Russian Journal of Cardiology*. 2022.
23. Gaetti-jardim E, Marcelino SL, Feitosa AC, et al. Detection of bacteria in atherosclerotic plaques of patients with coronary artery disease by polymerase chain reaction. *Anaerobe*. 2009;15(3):89-92.
24. Hansen GM, Greve JH, Greve ML. Pseudomonas aeruginosa microcolonies in coronary thrombi. *Eur J Clin Microbiol Infect Dis*. 2016.
25. Tungland B. Dysbiosis of the microbiota: therapeutic strategies utilizing dietary modification, pro- and prebiotics and fecal transplant therapies in promoting normal balance and local GI functions. In: Elsevier; 2018:381-419. doi:10.1016/B978-0-12-814649-1.00009-0.
26. Gao M, Heng X, Jin J, Chu W. Gypenoside XLIX ameliorate high-fat diet-induced atherosclerosis via regulating intestinal microbiota, alleviating inflammatory response and restraining oxidative stress in ApoE^{-/-} mice. *Pharmaceuticals*. 2022.
27. Yan N, Wang L, Li Y, et al. Metformin intervention ameliorates AS in ApoE^{-/-} mice through restoring gut dysbiosis and anti-inflammation. *PLoS ONE*. 2021.